Pyridobenzodiazepinones, pharmaceutical compositions and method of use
thereof
    1.
    发明授权
    Pyridobenzodiazepinones, pharmaceutical compositions and method of use thereof 失效
    吡啶并二氮杂酮,药物组合物及其使用方法

    公开(公告)号:US4424222A

    公开(公告)日:1984-01-03

    申请号:US462183

    申请日:1983-01-31

    摘要: New pyridobenzodiazepinones of the formula ##STR1## are described wherein X represents oxygen, --NH-- or --NCH.sub.3 -- and R represents 1-methyl-4-piperidinyl or 4-methyl-1-piperazinyl group optionally substituted by a methyl group, or a 3.alpha.- or 3.beta.-tropanyl group, and the nontoxic pharmaceutically acceptable acid addition salts thereof. The specification also describes processes for preparing these compounds, pharmaceutical compositions containing these compounds and new intermediate products used in preparing them. The compounds of formula I have antiulcerative effects and an inhibitory effect on gastric acid secretion, without the side effects such as dryness of the mouth and mydriasis which occur with other substances having an anticholinergic activity.

    摘要翻译: 描述了式(I)的新的吡啶并苯并二氮杂酮,其中X表示氧,-NH-或-NCH 3 - ,R代表1-甲基-4-哌啶基或4-甲基-1-哌嗪基,任选被甲基取代 ,或3α-或3β-丙酰基,以及其无毒的药学上可接受的酸加成盐。 本说明书还描述了制备这些化合物的方法,含有这些化合物的药物组合物和用于制备它们的新的中间产物。 式I化合物具有抗溃疡作用和对胃酸分泌的抑制作用,而没有与具有抗胆碱能活性的其它物质发生的口腔干燥和散瞳等副作用。

    Substituted dibenzodiazepinones
    8.
    发明授权
    Substituted dibenzodiazepinones 失效
    取代的二苯并二氮杂酮

    公开(公告)号:US4447434A

    公开(公告)日:1984-05-08

    申请号:US462149

    申请日:1983-01-31

    摘要: The specification describes new substituted dibenzodiazepinones of formula ##STR1## wherein R.sub.1 is hydrogen or chlorine atom and R is (1-methyl-4-piperidinyl)methyl, (1-methyl-1,2,5,6-tetrahydro-4-pyridinyl)methyl,1-methyl-1,2,5,6-tetrahydro-4-pyridinyl, (1-methyl-4-piperidinylidene)methyl,(2,3-dehydro-8-methyl-8-aza-bicyclo[3,2,1]oct-3-yl)-methyl, (8-methyl-8-aza-bicyclo[3,2,1]oct-3-ylidene)-methyl or an endo-or exo-(8-methyl-8-azabicyclo[3,2,1]oct-3-yl)methyl each being optionally substituted by one or two methyls on the heterocyclic ring, and the nontoxic, pharmaceutically acceptable acid addition salts thereof, processes for preparing them and pharmaceutical compositions containing these compounds.The compounds of formula I have an antiulcerative effect and an inhibitory effect on the secretion of gastric substances having anticholinergic activity, such as dryness of the mouth and mydriasis.

    摘要翻译: 该说明书描述了式(Ⅰ)的新的取代二苯并二氮杂酮,其中R 1是氢或氯原子,R是(1-甲基-4-哌啶基)甲基,(1-甲基-1,2,5,6-四氢 - 4-吡啶基)甲基,1-甲基-1,2,5,6-四氢-4-吡啶基,(1-甲基-4-亚哌啶基)甲基,(2,3-脱氢-8-甲基-8-氮杂 - 双环[3,2,1]辛-3-基) - 甲基,(8-甲基-8-氮杂 - 双环[3,2,1]辛-3-基) - 甲基或内 - 或外 - - (8-甲基-8-氮杂双环[3,2,1]辛-3-基)甲基,其各自任选被杂环上的一个或两个甲基取代,及其无毒的药学上可接受的酸加成盐,用于 制备它们和含有这些化合物的药物组合物。 式I化合物具有抗溃疡作用和对具有抗胆碱能活性的胃物质分泌的抑制作用,例如口干和散瞳。